This PR has slightly more detail than the one issued by IDRA in December (#msg-57983764).
IMO-2125 is a TLR9 agonist that being positioned as a replacement for interferon. However, the phase-1 data in this study were not clearly better in the IMO-2125 + ribavirin arms than in the SoC control arm. Moreover, the 0.16mg/kg weekly dose of IMO-2125 produced better results than either the 0.32mg/kg weekly dose or the 0.16mg/kg twice-weekly dose, a puzzling outcome.